tsha-101
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 12, 2021 (NCT04798235)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bifunctional protein NCOATSupplementation
OGA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04798235 | Phase 1/Phase 2 (Phase 2) | Mar 12, 2021 | Canadian Glycomics Network (GlycoNet), Queen's University, Belfast, Taysha Gene Therapies, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Glycomics Network (GlycoNet) | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Queen's University, Belfast | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Taysha Gene Therapies, Inc. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1